Last reviewed · How we verify
PA32540 and celecoxib — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PA32540 and celecoxib (PA32540 and celecoxib) — POZEN.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PA32540 and celecoxib TARGET | PA32540 and celecoxib | POZEN | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PA32540 and celecoxib CI watch — RSS
- PA32540 and celecoxib CI watch — Atom
- PA32540 and celecoxib CI watch — JSON
- PA32540 and celecoxib alone — RSS
Cite this brief
Drug Landscape (2026). PA32540 and celecoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/pa32540-and-celecoxib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab